In vivo MR spectroscopy (MRS) provides information about metabolite concentrations in tissue. Recently, citrate (Cit) was detected by MRS in subgroups of pediatric brain tumors. Citrate is an intermediate in the tricarboxylic acid (TCA) cycle and accumulates in tissue when the glycolytic rate exceeds the TCA cycle activity, a feature of malignant tumors. Currently, no practical indicators allow clinicians to predict risk for malignant progression of pediatric astrocytomas (WHO grade II). Medical records and citrate concentrations measured with in vivo MRS of 29 pediatric astrocytomas were reviewed. This included six astrocytomas (WHO grade II) with stable disease (indolent-LGA) for more than 2 years and 7 aggressive grade II astrocytomas (aggressive-LGA), 13 anaplastic astrocytomas (WHO grade III), and 3 glioblastomas (WHO grade IV) with disease progression within 2 years. Citrate was observed in all aggressive-LGA, and the mean citrate concentration was significantly higher in this group than in indolent-LGA (4.1 + 1.1 vs 0.6 + 0.8 mmol/kg; P , 0.0001). There was no consistent pattern for citrate in anaplastic astrocytoma and glioblastoma, with citrate prominent in some lesions while undetectable in others. It is unclear whether citrate accumulation occurred due to fundamental defects of citrate regulation, such as isocitrate dehydrogenase mutations, or secondary to altered physiological conditions. Nonetheless, prominent citrate identified a subgroup of pediatric grade II astrocytomas destined for aggressive behavior. Citrate was not specific for poor outcome as it was not detectable in all high-grade astrocytomas. Among high-grade astrocytoma, tumors with prominent citrate may constitute a metabolic subclass.
INTRODUCTION: Bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor A, is effective as a second-line treatment for both glioblastoma multiforme (GBM) and radiation-induced brain necrosis. However, treatment has a high risk of complications and a large number of tumor treatment failures. METHODS: Retrospective analysis of apparent diffusion coefficient (ADC) and fractional anisotropy (FA) values of regions of interest (ROIs) involving the contrast enhancing portion (CE), non-enhancing T2 hyperintense portion (NE), and contralateral normal-appearing brain (similar location to the CE) were obtained over consecutive studies in 14 patients with GBMs and 11 patients with radiation-induced brain necrosis. Longitudinal changes, group differences, and relationship with treatment related complications/ failure were analyzed. RESULTS: When the ratio of ADC values of CE ROI over contralateral ROI at baseline was low, it predicted failure or complications with therapy in both tumor and necrosis patients. When the ratio was , 1.33, 2 GBM patients had progression while 2 GBM and 2 necrosis patients had vascular complications (venous thromboembolic event or stroke), with 1 necrosis patient also needing an additional dose. If the ratio was 1.35-1.86, there were 3 vascular complications, 3 non-vascular complications (myelosuppression or infection), 1 progression of GBM, 2 re-treatments, and 6 without problems (total, 8 GBM and 6 necrosis). All 5 patients with ratios .1.87 were without problems (2 GBMs and 3 necrosis). ADC values were statistically higher and FA values lower for necrosis compared to GBM for both CE and NE, but group values overlapped, limiting their clinical utility. There was more reduction in CE ADC values for necrosis at 6 weeks after treatment than tumor, corresponding to diminished enhancement. CONCLUSION: Baseline normalized ADC ratios appear highly predictive of problems with bevacizumab treatment, but further investigation is necessary to prospectively test this correlation and understand the underlying physiology. Promoter methylation of O6-methylguanine-DNA methyltransferase (MGMT) is associated with a favorable prognosis in glioblastoma multiforme (GBM) and has been hypothesized to occur early in tumor transformation of glial cells. Thus, a possible link exists between the site of malignant transformation and MGMT promoter methylation status. Using the Analysis of Differential Involvement (ADIFFI) statistical mapping technique in a total of 384 patients with GBM, we demonstrate that human de novo GBMs occur in a high frequency contiguous with the posterior subventricular zone (SVZ); MGMT promoter methylated GBMs are lateralized to the left hemisphere, while MGMT unmethylated GBMs are lateralized to the right hemisphere; and tumors near the left superior temporal gyrus to the temporal-parietal junction have a significantly longer overall survival compared with tumor occurring elsewhere, independent of treatment or MGMT methylation status (Cox proportional hazard analysis; KPS, P , 0.0001; MGMT methylation status, P , 0.0001; confluent with ADIFFI "cluster," P ¼ 0.0072).
RA-05. ANATOMIC LOCALIZATION OF O6-METHYLGUANINE

RA-06. FUNCTIONAL DIFFUSION MAPS IN FLAIR ABNORMAL REGIONS PREDICT SURVIVAL IN BOTH NEWLY DIAGNOSED
GLIOBLASTOMA TREATED WITH RADIOCHEMOTHERAPY AND RECURRENT GLIOBLASTOMA TREATED WITH BEVACIZUMAB Benjamin M. Ellingson, Timothy F. Cloughesy, Taryar Zaw, Robert Harris, Shadi Lalezari, Phioanh L. Nghiemphu, Korosh Motevalibashinaeini, Albert Lai, and Whitney B. Pope; University of California Los Angeles, Los Angeles, CA Functional diffusion mapping (fDM), a technique that uses voxel-wise changes in apparent diffusion coefficient (ADC) calculated from diffusion MRI, has shown great promise as both an early predictor of response to therapy and as a clinical monitoring tool for patients with malignant gliomas. Despite promising initial findings in conventional cytotoxic therapy and anti-angiogenic therapies, fDMs have only been evaluated in a relatively small cohort of glioma patients. Furthermore, glioblastoma patients were not evaluated exclusively, suggesting these early results may have been sensitive to tumor grade and not solely on response, as these factors were not originally accounted for in initial studies. In the current study, we evaluated the prognostic ability of early fDMs calculated in FLAIR abnormal regions before and after radiochemotherapy in 94 patients with de novo glioblastoma as well as before and after bevacizumab treatment in 77 patients with recurrent glioblastoma. Results suggest newly diagnosed patients having a volume of tissue exhibiting a significant decrease in ADC (eg, hypercellular tissue) greater than 25cc had a significantly shorter progression-free survival (log-rank, P ¼ 0.001) and overall survival (log-rank, P ¼ 0.0057). Additionally, recurrent glioblastoma patients treated with bevacizumab having a volume of tissue exhibiting a significant decrease in ADC greater than 13cc had a significantly shorter overall survival (log-rank, P ¼ 0.003). Results support the hypothesis that fDMs are predictive biomarkers in patients with glioblastoma, independent of treatment paradigm.
RA-07. RESTING-STATE NETWORK PROPERTIES AND SEIZURE OUTCOME AFTER BRAIN TUMOR RESECTION Linda Douw, Marieke E. Van de Nieuwenhuijzen, Jan J. Heimans, Johannes C. Baayen, Cornelis J. Stam, and Jaap C. Reijneveld; VU University Medical Center, Amsterdam, Netherlands Brain tumors are accompanied by a range of symptoms, including cognitive deficits and epilepsy. Resection is often performed, but the outcome of neurosurgery unexplainably varies across individual patients. A new method of investigating the functional status of the brain is by applying "network theory" to neurophysiological measurements. By calculating functional connectivity between different brain areas, a network of the brain can be constructed. The brain network tends to be a "small world," combining both local specialization and overall global integration. It is clear that brain networks are suboptimal (and thus less small world) in brain tumor patients. The aim of this study was assessing the effects of brain tumor resection on functional connectivity and network properties and correlating them with epilepsy outcome, in order to investigate whether neurosurgery changes the brain network to a more normal organization. Resting-state magnetoencephalography recordings of 15 brain tumor patients before and after tumor resection were studied. Two measures of functional connectivity were calculated in 5 frequency bands ranging from delta to beta. Weighted networks were constructed and several network properties (path length for global integration, clustering coefficient for local specialization, overall small-world-ness) were calculated. Total SL scores increased in the beta band after surgical intervention, while a decrease in interhemispheric theta band phase lag index has been reported previously. After resection, SL-based clustering coefficient and small-world index increased in the low alpha band, indicating more optimal network architecture after surgery. Moreover, patients who were seizure-free after surgery showed an increase in small-world index, while those still suffering from seizures did not show a significant change in small-world topology after tumor resection. The changes in functional connectivity and network properties observed after tumor resection seem to indicate normalization of these characteristics, which is correlated with postoperative seizure outcome. [VD] ) correlate with increased tumor proliferation, while increased unidirectional AMT uptake rates (K) are caused by increased tryptophan metabolism via the immuno-modulatory kynurenine pathway. We aimed to determine whether these kinetic tryptophan PET variables are related to tumor perfusion. METHODS: Fifteen patients (age, 21-79 years; mean, 54 years) with a newly diagnosed brain tumor (n ¼ 6) or previously treated brain tumor with possible tumor recurrence (n ¼ 9) underwent dynamic AMT-PET scanning and perfusion MRI. AMT-PET scans were analyzed to calculate lesion/contralateral cortex standard uptake value (SUV)-, VDand K-ratios and to compare these ratios with lesion perfusion (cerebral blood volume [CBV] ) and histologic grade of tumors. RESULTS: Eleven lesions (high-grade gliomas) showed increased CBV (high-perfusion lesions), and 4 lesions (3 low-grade tumors and 1 post-treatment lesion with likely radiation necrosis) showed no increase in CBV on perfusion MRI (lowperfusion lesions). The 1 low-perfusion lesion with likely radiation necrosis also showed no increase in AMT SUV on PET. All other lesions showed high AMT SUVs. On PET kinetic analysis, AMT transport rates (VD-ratios) were twice as high in high-perfusion as low-perfusion lesions (mean, 2.9 + 0.7 vs 1.4 + 0.5, respectively; P ¼ 0.002). However, tryptophan K-ratios were unrelated to tumor perfusion (P ¼ 0.98). In 7 patients who had surgery after AMT-PET, tumor grades showed a strong correlation with VD-ratios (Spearman's rho ¼ 0.94, P ¼ 0.001) but not K-ratios (P ¼ 0.4). CONCLUSIONS: Brain tumors of various grades demonstrate high AMT SUVs regardless of perfusion status. High-perfusion lesions show higher tryptophan transport rates (VD-ratios) and also have a higher tumor histologic grade. Increased unidirectional AMT uptake rates (K-ratios) are unrelated to tumor perfusion and may be caused by kynurenine pathway activation, which is thought to be a mechanism of tumor immune resistance. and relative. The use of image intensity transformation algorithms provides a mechanism for obtaining quantitatively similar CBV maps in the same intensity scale. In the current study, we compare "standardization," "Gaussian normalization," and "Z-score normalization" CBV transformation techniques. To accomplish this, the coefficient of variance (CV) in normal-appearing white matter and contrast-to-noise ratio (CNR) was compared between the 3 CBV transformations across 5 different MR scanners in 96 patients with gliomas. Results suggest Gaussian normalization of CBV maps provided the lowest CV in normal white matter (19% vs 22%-31% for other techniques), and was statistically better than the other techniques when different MR scanners were used at follow-up. Additionally, Gaussian normalization provided the highest tumor contrast-to-noise for all tumor grades (approximately 25% higher) compared with other techniques. In summary, results suggest Gaussian normalization of leakage-corrected CBV maps may be the best choice for image intensity correction for use in large scale, multicenter clinical trials where MR scanners and protocols vary widely. Amino acid and amino acid analog positron emission tomography (PET) tracers are a unique class of brain tumor imaging agents that have demonstrated high specificity for detecting brain tumor recurrence because of high tumor uptake and low uptake in normal brain. In the current study, we examined the prognostic ability for voxel-wise changes in 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine (18F-FDOPA) PET uptake, or 18F-FDOPA PET parametric response maps (PRMs), to predict survival in 17 recurrent glioblastoma patients evaluated before and after treatment with bevacizumab. Results suggest the percentage of pre-treatment contrast-enhancing tumor that showed a significant decrease in 18F-FDOPA uptake was linearly correlated with overall survival (Pearson correlation coefficient, R 2 ¼ 0.2832, P ¼ 0.0279). Patients exhibiting a decrease in 18F-FDOPA PET after bevacizumab in more than 25% of pre-treatment contrast-enhancing tumor regions had more than a 6-month median survival advantage (log-rank, P ¼ 0.0098).
RA-08. TRYPTOPHAN KINETICS MEASURED BY AMT-PET IN LOW-PERFUSION AND HIGH-PERFUSION BRAIN TUMORS
RA
RA-11. A NEW METHOD FOR DETECTING CANCER USING F-18 FDG DUAL-POINT PET SUBTRACTION CO-REGISTERED TO MR Mark A. Ahlman and Pierre Giglio; Medical University of South Carolina, Charleston, SC Cancer continues to retain F-18 fluorodeoxyglucose (FDG) at delayed imaging time points, whereas inflammatory or normal tissue releases tracer sooner. Using this mechanism, early evidence has shown that dual-point or delayed imaging of cancer with FDG can help differentiate inflammatory or normal tissue from neoplastic disease. We describe 2 cases where our novel procedure of Dual-Point PET Subtraction Co-registered to MR (DPPSCOM) with FDG appears to show excellent qualitative and quantitative spatial resolution for recurrent disease. Patient 1 has a left parietal metastasis from breast cancer previously treated with chemotherapy and radiation. MR spectroscopy was suggestive of recurrence of disease along the lateral border of the lesion. Ten-minute early and delayed PET images of the brain were taken at 60 and 240 minutes uptake time, respectively. Standard uptake value measurements and visual analysis did not disclose any significant abnormalities or differences in metabolism between the time points. DPPSCOM clearly showed "positive" areas that directly corresponded with the positive MR spectroscopy region of interest. Patient 2 has a GBM treated with chemotherapy and radiation. Regional cerebral blood volume (CBV) by MR was suggestive of recurrence. Using a similar technique as with patient 1, DPPSCOM showed excellent correlation with CBV but also showed a gradient of information that appears to demonstrate the heterogeneous activity of cancer with useful quantitative information. Early experimentation with DPPSCOM demonstrates exciting results and employs a technique that utilizes the same radiotracer, equipment, and staff available to most tertiary nuclear medicine departments. DPPSCOM may be useful for higher yield and accurate 3D biopsy and surgical planning, radiation treatment planning, and increased sensitivity and specificity of FDG PET for evaluating cancer, particularly for the CNS. Further study is ongoing to technically validate the procedure and idealize the protocol for easy processing, accurate interpretation, and integration into intervention planning software. INTRODUCTION: Antiangiogenic therapy is associated with sometimes dramatic drops in the apparent diffusion coefficient (ADC). Low ADC in tumors is often a poor prognostic sign, as it in part reflects tumor cellularity. However, antiangiogenic therapy has an edema-decreasing effect that also lowers ADC, and the significance of large drops in ADC while on such therapy is unknown. METHODS: MRI scans of 19 patients enrolled in the North Central Cancer Treatment Group phase II trial of bevacizumab (BEV)/sorafenib (SOR) in the treatment of recurrent glioblastoma were evaluated at baseline (n ¼ 19), at day 3 (n ¼ 8), and at 4 weeks (n ¼ 19), blinded to clinical outcomes. Regions of interest were drawn around enhancing tumor on each scan, and ADC statistics were calculated for baseline ADC and change in ADC, including the use of 2-mixture generalized lambda distributions to model the ADC histogram data. Linear models along with Kaplan-Meier and Cox proportional hazards models were used to correlate ADC metrics with progression-free survival (PFS) and overall survival (OS). RESULTS: The change in ADC from baseline to 4 weeks following initiation of BEV/SOR correlated with survival statistics. Specifically, the Kaplan-Meier survival curves were less favorable for those with less than a 25% reduction in mean ADC (hazard ratio ¼ 3.9, P ¼ 0.018 for OS, and hazard ratio ¼ 4.8, P ¼ 0.012 for PFS). Changes in ADC by day 3 were not associated with survival. PFS tended to increase as the mean ADC of the lower distribution of ADC for baseline scans increased (slope ¼ 0.334, P ¼ .071). CONCLUSION: A decrease of more than approximately 25% in mean ADC following the initiation of antiangiogenic therapy represents a favorable prognostic factor. This is in contradistinction to prior to initiation of antiangiogenic therapy, when a lower ADC has been previously shown to be a negative prognostic sign. University of Utah School of Medicine, Salt Lake City, UT INTRODUCTION: Neoplastic meningitis (NM) affects at least 5% of all cancer patients. If diagnosed early, intrathecal chemotherapy can ameliorate neurologic symptoms and prolong survival in this patient population. Currently, the gold standard in diagnosis is by cerebrospinal fluid (CSF) cytology, which has a poor sensitivity of 40-65%. The level of lactic acid in the CSF is reliably elevated in these patients. MR spectroscopy can characterize the concentration of clinically relevant metabolites. The aim of this study was to determine the diagnostic utility of ventricular MRI spectroscopy (MRS) in patients with suspected NM. METHODS: We performed a retrospective chart and imaging review of 21 patients with known cancer and progressive neurologic symptoms suspicious for NM. Data collected on each of the patients included demographic information and CSF cytology. Ventricular MRS was reviewed by an independent blinded radiologist. RESULTS: Of the 21 patients, 15 (71%) were male. The sensitivity and specificity for MRS was 93% and 71%, respectively, with a positive likelihood ratio of 3.3 and diagnostic odds ratio of 32.5. Previous studies have shown that 19% of patients with known cancer and neurologic findings have NM. Using these data with our results, the chance of a cancer patient with neurologic findings having NM with a positive MRS becomes 43%, and if the MRS is negative, the chance becomes 2.3%. CONCLUSIONS: Ventricular MRS is a reliable non-invasive diagnostic tool with a high sensitivity and specificity that can be used in diagnosis of NM. Further studies are needed to confirm its utility in prognostication and effect on survival.
RA-13. NOVEL USE OF MR SPECTROSCOPY TO DETECT CEREBROSPINAL FLUID LACTATE AND DIAGNOSE NEOPLASTIC MENINGITIS
Our institution has been conducting immunotherapy targeting the Wilms' tumor 1 (WT1) gene product in patients with recurrent high-grade gliomas (HGGs) as a clinical trial and has reported preferable results (Izumoto et al., J Neurosurg. 2008) . Although conventional gadolinium-enhanced MRI (Gd-MRI) has initially been used for monitoring treatment response, it has become clear that Gd-MRI does not reflect prognosis, requiring a more robust imaging evaluation system for monitoring WT1 immunotherapy. As 11C-methionine positron emission tomography (MET-PET) has the capability to reflect tumor cell density and proliferative activity at the tumor core, we have performed a voxel-wise functional analysis of preand post-treatment MET-PET in WT1 immunotherapy and compared with the overall survival (OS). Twelve recurrent malignant glioma patients were included in the study. OS after initiating WT1 immunotherapy (OSWT1) was compared with 1) volume change of contrast area of the tumor on Gd-MRI, 2) change of maximum (T/Nr max) and average (T/Nr ave) uptake of 11C-methionine, and finally 3) a more detailed voxel-wise functional analysis data of MET-PET pre-and post-WT1 immunotherapy treatment. Voxel-wise functional analysis was able to identify the following 3 areas within the tumor core: area with no-change of 11C-methionine uptake pre-and post-treatment (NC area), area with increased 11C-methionine uptake post-treatment (+2SD area), and area with decreased 11C-methionine uptake post-treatment (-2SD area). While Gd-MRI did not correlate with OSWT1 (R 2 ¼ 0.055), changes in T/Nr max and T/Nr ave showed moderate correlation (R 2 ¼ 0.42, R 2 ¼ 0.20, respectively) and percentage of -2SD area showed the best correlation (R 2 ¼ 0.49) with OSWT1. This study describes the limited value of Gd-MRI and highlights the necessity of a more advanced imaging evaluation technique for monitoring immunotherapy in HGG patients. It also shows the potential of voxel-wise functional analysis of MET-PET for monitoring treatment response in immunotherapy for HGG. ) as an in vivo DNA synthesis marker usable as a positron emission tomography (PET) molecular imaging probe. This is the first clinical PET probe ever reported; its incorporation into the DNA fraction of tumors was biochemically confirmed (Toyohara et al. J Nucl Med. 2006; 47:1717) . In our first clinical trials of using this probe for patients with malignant brain tumor, we aimed to examine if this new imaging technique may provide useful information that cannot be obtained by other present imaging methods. METHODS: Nine patients with malignant brain tumors (6 malignant glioma, 2 metastatic tumor, and 1 malignant lymphoma) and 3 normal controls underwent [ 
RA-15. INITIAL CLINICAL TRIALS OF CARBON-11-LABELED 4DST FOR MALIGNANT BRAIN TUMORS AS
RA-16. DIFFUSION IMAGING PARAMETERS VARY WITH TREATMENT REGIMEN FOR PATIENTS WITH NEWLY
DIAGNOSED GLIOBLASTOMA MULTIFORME Laleh Jalilian, Emma Essock-Burns, Soonmee Cha, Susan Chang, Michael Prados, Nicholas Butowski, and Sarah Nelson; University of California, San Francisco, San Francisco, CA OBJECTIVE: The purpose of this study was to evaluate early changes in volumes and apparent diffusion coefficient (ADC) in the contrast-enhancing lesion (CEL) and non-enhancing lesion (NEL) of post-surgical newly diagnosed grade IV glioma patients being treated with radiotherapy (RT) and 3 different treatment regimens. METHODS: Ninety-nine patients were evaluated: 31 with temozolomide (TMZ) alone, 41 with TMZ and an antiprotein kinase C (PKC) agent, and 27 with TMZ and an anti-vascular endothelial growth factor (VEGF) agent. MR data were acquired at baseline (post-surgical resection, pre-RT), mid-RT, and post-RT using a 3-T MR scanner. All subjects had at least 2 of these 3 scans available for analysis. Tumor volumes and normalized ADC were calculated for the CEL and NEL. Wilcoxon sign-rank and rank-sum tests were used to characterize differences amongst the treatment regimens. RESULTS: From pre-to post-RT, patients receiving RT + TMZ alone demonstrated no significant change in CEL or NEL volumes. The median normalized ADC (nADC) in the CEL and NEL significantly increased (P , 0.0004 and P , 0.0014). Patients receiving the anti-PKC agent demonstrated a significant decrease in CEL volume (P , 0.0013) but no change in NEL volume. The median nADC increased significantly in the CE and NEL (P , 0.0001 and P , 0.0033). Patients receiving the anti-VEGF agent demonstrated a significant decrease in CEL and NEL volume (P , 0.0007 and P , 0.0008), while the median nADC in the CEL and NEL remained stable. CONCLUSIONS: There were clear differences in patterns of response between the 3 patient groups. Although both agents reduce the CEL, the anti-VEGF agent reduced edema more effectively than the anti-PKC agent and reduced the magnitude of the RT effect more than either the anti-PKC agent or TMZ alone. While it is too early to evaluate the relationship of these early changes to survival, this will be achieved as soon as the data become available. High-grade (atypical or anaplastic) meningiomas grow aggressively and recur frequently, resulting in poor prognosis. As the utility of noninvasive treatments for brain tumors increases, it is becoming important to assess the likelihood that a tumor is not benign before treatment initiation. We attempted to find the characteristics to determine risk factor for high-grade meningioma on MR imaging before operation. We reviewed 65 meningiomas (benign, 39 cases; high-grade, 26 cases) and assessed 4 characteristics: 1) tumor-brain interface (TBI) on T1-weighted imaging; 2) capsular enhancement: the layer of the brain-tumor interface on T1-weighted gadolinium-enhanced imaging (T1Gd); 3) heterogeneity on T1Gd; and 4) tumoral margin on T1Gd. All characteristics were useful to distinguish a high-grade meningioma from a benign one according to the univariate analysis. On multivariate regression analysis, unclear TBI and heterogeneous enhancement were risk factors for high-grade meningioma. In the case of a meningioma with unclear TBI and heterogeneous enhancement, prediction rate of high-grade meningioma is 97.9%, whereas 88% of benign meningiomas showed clear TBI and homogeneous enhancement. Our data suggest that conventional MR imaging is still useful to detect malignant meningioma, although some advanced MR imaging techniques have shown potential for differentiating benign and high-grade meningiomas.
RA-17. PREDICTION OF HIGH-GRADE MENINGIOMA BASED ON THE ASSESSMENT OF PREOPERATIVE MRI
RA-18. PROGNOSTIC ROLE OF DIFFUSION-WEIGHTED MRI IN PEDIATRIC OPTIC PATHWAY GLIOMA
Kristen Yeom, Jarrett Rosenberg, Jalal B. Andre, Paul G. Fisher, Michael S. Edwards, Patrick D. Barnes, and Sonia Partap; Stanford University, Palo Alto, CA PURPOSE: Magnetic resonance imaging (MRI) is commonly used in diagnosis and surveillance for optic pathway glioma (OPG). We investigated the role of diffusion-weighted (DW) MRI in assessing risk of progression and need for therapy in OPG. METHODS: Among 36 children with OPG, 13 patients (median age, 3 years; range, 5 months to 6 years) with tumor volume . 1 cm 3 who had pre-treatment DW MRI (echo planar imaging [EPI] technique, b ¼ 1,000 sec/mm 2 , 3-directions) were retrospectively reviewed, after institutional review board approval. Both sporadic (n ¼ 7) and NF-1-associated optic gliomas (n ¼ 6) were included. Tumors confined to the intraconal optic nerve were excluded due to technical limitation of EPI DWI within the bony orbit. Apparent diffusion coefficient (ADC) of the solid portions of the tumor was measured using the region of interest method, both
at baseline and on follow-up MRI. RESULTS: For the 13 patients, 7 required treatment (surgery and/or chemotherapy) for symptomatic tumor progression (5 sporadic OPG and 2 cases of NF-1 INTRODUCTION: Standard measures for assessing therapy response for patients with glioblastoma multiforme (GBM) depend on volume changes in the anatomic lesion in MR images. Because anti-angiogenic therapies induce vascular remodeling that may alter the appearance of contrast enhancing lesion (CEL) and T2 lesion (T2L), there is a need for alternative response assessment metrics. Dynamic Susceptibility Contrast (DSC) imaging is a promising method for this application because it provides a measure of elevated relative cerebral blood volume (rCBV), a marker of increased perfusion and malignant tumor. METHODS: 103 patients newly diagnosed with GBM were imaged on a 3-T MR scanner. This study population excluded any patients thought to have progressed by 2 months into therapy, to avoid misinterpretation due to pseudoprogression. All subjects received radiotherapy and temozolomide; 35 received no anti-angiogenic therapy, 27 received an anti-vascular endothelial growth factor agent, and 41 received an anti-protein kinase C agent. DSC data were acquired with a gradient-echo, echo-planar sequence (TE/TR ¼ 54-56/1,500-2,000 ms, flip ¼ 358, field of view ¼ 24 x 24 cm 2 ). The CEL and T2L were contoured on the T1-weighted post-gadolinium SPGR and T2-weighted FLAIR sequences, respectively. The rCBV lesion was defined by the region within the T2L with greater than twice the normal-appearing white matter value. Baseline and 2-month time points are reported. RESULTS: While patients on all treatment arms had significantly decreased CEL volume from baseline to 2 months (sign-rank: p , .007 for each arm), only patients treated with anti-VEGF therapy had significantly decreased rCBV volumes (sign-rank, p ¼ .007). CONCLUSIONS: Tracking rCBV lesion volume in GBM patients shows differences in early response that were not detected by changes in CEL volume. We are continuing to follow these patients with DSC imaging through their treatment course and, as the dataset matures, we will evaluate changes in rCBV lesion at the time of recurrence for all 3 patient populations. Accurate volume measurement is important in predicting outcome and defining management plans in patients with low-grade gliomas (LGGs). Volume assessments are potentially more accurate than linear measurements. This work aims to study the initial impact of semiautomated volumetric lesion analysis in the clinical setting. METHODS:
RA-20. SEMI-AUTOMATED VOLUMETRIC ANALYSIS OF LOW-GRADE GLIOMAS
LGG patients were followed up with volume FLAIR sequences that gave high tumor-to-brain contrast. A semi-automated assessment of tumour volume (MIM software, www.mimsoftware.com) was based on a thresholding and region-growing technique. Longitudinal studies over time were spatially co-registered and difference images allowed a visible assessment of areas of apparent tumor growth. A total of 173 studies have been processed in 85 patients (44 men, 41 women; mean age, 44.13 years). Histology was available in 22 patients (6 WHO grade II gliomas, 7 WHO grade III gliomas, 1 WHO grade II oligodendroglioma, 6 WHO grade III anaplastic oligodendrogliomas, and 2 WHO IV gliomas). The remaining 63 patients were presumed LGGs undergoing radiological follow-up only. Patients had between 1 and 6 studies over up to 3 years of follow-up. RESULTS: Calculated tumor volumes were 0.05-160.67 ml. In patients with multiple studies, it was possible to calculate an equivalent annual growth rate. High initial (. 30%) or acceleration in growth rate was noted in 16 patients, which triggered either biopsy or surgical excision in 8 patients. Six of these patients demonstrated high-grade glioma (WHO grade III or IV) on histology. CONCLUSION: Semi-automated analysis of tumor volume was efficiently estimated via the MIM software. This study is still ongoing and long-term follow-up data on many patients is therefore currently lacking. Knowledge of the pattern of growth has often changed clinical management. This study confirmed that quantitative tumor volume analysis can be performed in a clinical setting, which informs management decisions. Aggressive-appearing pontine neoplasms, which manifest on MRI as infiltrating, expansile, and occasionally enhancing, are often assumed to represent diffuse intrinsic pontine gliomas, and are frequently treated without biopsy. We present a case of a 22-month-old female who presented with a wide-based, unsteady gate, facial asymmetry, and disconjugate gaze that developed over a period of weeks. MRI showed a non-enhancing, lobulated, expansile pontine mass, with satellite lesions. Because of the atypical imaging characteristics, biopsy was performed. The unexpected diagnosis of pilomyxoid astrocytoma, a tumor type not previously described in this location, was made. This case should serve to expand the radiographic differential diagnosis of atypical pontine tumors, and we recommend consideration of biopsy to confirm pathologic diagnosis.
RA-21. PILOMYXOID ASTROCYTOMA OF THE PONS
RA-22. ROLE OF NON-MODEL-BASED SEMI-QUANTITATIVE INDICES OBTAINED FROM DCET1 MR PERFUSION IN DIFFERENTIATING PSEUDO-PROGRESSION FROM TRUE-PROGRESSION
Rajan Jain, Jayant Narang, Ali Syed Arbab, Lonni Schultz, Lisa Scarpace, Tom Mikkelsen, and Abbas Babajni-Feremi; Henry Ford Health System, Detroit, MI Increasing use of various combinations of aggressive chemotherapy and radiation therapy for gliomas has led to complex post-treatment morphologic imaging appearance, and "pseudo-progression" is not uncommon in a busy neuro-oncologic practice. The purpose of this retrospective study was to evaluate the role of non-model-based semi-quantitative indices obtained from DCET1 MR perfusion (DCET1MRP) in differentiating pseudo-progression from true progression. Forty-eight (30%) of 162 previously treated glioma patients showed a recurrent or progressive enhancing lesion (RPEL) within 3 months of radiotherapy. Thirty patients who had DCET1MRP studies were included in the final analysis. Semi-quantitative indices were derived from DCET1MRP enhancement curves: maximum slope of enhancement in the initial vascular phase (MSIVP), normalized MSIVP (nMSIVP), normalized slope of the delayed equilibrium phase (nSDEP), and initial area under the normalized timeintensity curve (nIAUC) at 60 and 120 sec (nIAUC 60 and nIAUC 120 ). These patients were classified into pseudo-progression (stable or improving RPEL on follow-up imaging without any change in treatment) and true progression (worsening RPEL with no change in treatment or stable RPEL with additional anti-angiogenic treatment). Seven (23.3%) patients were diagnosed with pseudo-progression and 23 (76.7%) as true progression. There was a statistically significant difference between these 2 groups (P , 0.05) with pseudo-progression showing lower mean MSIVP (8.3 vs 15.7), lower nIAUC 120 (68.1 vs 79.1), nIAUC 60 (27.3 vs 33.3), and higher nSDEP (13.8 x 10 25 vs 7.3 x 10
25
). nMSIVP values were not statistically different between the 2 groups. Thirteen (56%) of 23 trueprogression patients received anti-angiogenic therapy and 10 (76%) of these showed favorable imaging response. Our results show that semiquantitative indices derived from DCET1MRP may differentiate pseudoprogression from true progression. Also, changing treatment based on MSIVP values at the time of diagnosis of RPEL may be beneficial as evidenced by imaging response noted in 76% of true-progression cases who received anti-angiogenic therapy.
Abstracts iii140
NEURO-ONCOLOGY † N O V E M B E R 2 0 1 1 The purpose of this study was to evaluate the role of tumor blood volume estimated using DSC T2* MR perfusion in survival prediction compared to the molecular subclasses of glioblastoma multiforme (GBM). Fifty-seven patients with treatment-naïve GBM underwent DSC T2* MR perfusion studies at 2 different institutes. Of these, 50 patients had gene expression data available from TCGA. Relative cerebral blood volume (rCBV) maps were generated using NordicICE (Nordic Neuro Lab) software using leakage correction. rCBV max and rCBV mean of the contrast-enhancing part of the lesion (CEL) as well as rCBV NEL of the non-enhancing part of the lesion (NEL) were measured. All the patients were sub-classified into classical, mesenchymal, neural, and proneural based on Verhaak classification, and also into mesenchymal, proneural, and proliferative based on the Phillips classification system. We correlated the perfusion parameters with the molecular sub-classes as well as with patient survival. Cox regression was used to model the association of overall survival with perfusion parameters accounting for potential confounders. Additionally, we included each of the Verhaak and Phillips classification groups as predictors. P-values were derived from Wald chi-square tests of the hazard ratio. No statistically significant differences were noted for rCBV max and rCBV mean as well as rCBV NEL between the 4 classes using Verhaak or 3 classes using Phillips classification system. However, increasing rCBV measures appear to relate to poor survival in GBM. rCBV max (P ¼ 0.0131) seems to be the most significant regardless of the potential confounders (MR scanner type, patient age) or molecular classification. rCBV NEL showed marginally significant increasing risk of death (P ¼ 0.0555). Interestingly, the Verhaak classifier appears to have a confounding effect on the hazard ratio for rCBV mean (P ¼ 0.0299) and potentially to a lesser degree for rCBV NEL (P ¼ 0.0974), though not with rCBV max . It is additionally interesting that the Phillips subclasses neither associate with patient survival nor affect the association of rCBV measures with survival. Previous studies suggest that a significant number of glioblastoma multiforme (GBM) patients with radiological deterioration after chemoradiation do not suffer from tumor recurrence but from pseudoprogression induced by the treatment. Reliable distinction between these conditions is essential for appropriate patient management. We have recently demonstrated the advantages of a delayed contrast extravasation MRI methodology for depiction of subtle blood-brain barrier (BBB) disruption with high spatial resolution and high sensitivity to BBB abnormalities in ischemic stroke. Disruption patterns are clearly visualized on BBB function maps depicting the distribution of 3 permeability populations: fast, slow, and no permeability. In the current study, newly diagnosed GBM patients treated with the standard Stupp protocol undergo MRI 3 weeks after chemoradiation and every 2 months thereafter. BBB function data are acquired at 15/ 90 min post-Gd, enabling high sensitivity to slow permeability components. Preliminary results of 4 patients reaching 4.5 months follow-up are presented. In 2 patients suspected for progression/pseudoprogression, similar enhancing regions on T1-Gd, present entirely different permeability patterns. Moreover, a third patient with stable disease shows no fast component while the other 3 patients present 30-60% fast component. Regions of interest were defined on T1-Gd and the correlation between slow permeability in the first MRI and the change in tumor volume at 4.5 months was studied. Using the 15-min maps, a trend suggesting that a larger slow component is related with later decrease in lesion volume (R 2 ¼ 0.47, P , 0.08) was determined. The 90-min data provided significant correlation (R 2 ¼ 0.64, P , 0.03). Combining both time points resulted in a stronger correlation (R 2 ¼ 0.8, P , 0.007), confirming the additional/irredundant information obtained at 90 min. These preliminary results suggest that the unique vessel permeability characterization obtained here provides new valuable information that may be applied for prediction/determination of treatment effects. The correlation between initial permeability characteristics, their change in time, and patient outcome is yet to be seen.
RA-24. THE APPLICATION OF MRI FOR DISTINCTION
RA-25. ATYPICAL IMAGING APPEARANCE OF INTRACRANIAL
GRANULOCYTIC SARCOMA Nandita Guha-Thakurta and J.M. Debnam; The University of Texas MD Anderson Cancer Center, Houston, TX INTRODUCTION: Granulocytic sarcoma is a tumor that occurs in patients with acute myeloid leukemia (AML) and rarely involves the central nervous system. Here we report the first case of a ring-enhancing, intracranial granulocytic sarcoma and its management. CASE REPORT: A 26-year-old man with AML relapsed on chemotherapy. On presentation to the ER with fever and dizziness, imaging of the brain revealed no evidence of an intracranial abnormality. Due to absence of neurologic deficits and presence of positive blood cultures, broad-spectrum antimicrobials and antitoxoplasmosis drugs were started. A repeat MRI scan following development of a headache revealed a ring-enhancing mass in the left cerebral hemisphere. After a 10-day interval, a minimal increase in the size of the mass was noted on follow-up MRI, while diffusion-weighted imaging (DWI) did not reveal any restricted signal, excluding a pyogenic abscess. Following a nondiagnostic biopsy, the mass was surgically resected, and histological examination led to the diagnosis of granulocytic sarcoma. The patient received radiation therapy and stem cell transplant after surgery and is currently disease free. CONCLUSIONS: Intracranial granulocytic sarcomas are predominantly described as homogeneously enhancing extra-axial tumors and rarely as intra-axial lesions. Since their appearance as a ring-enhancing mass has not been reported before, DWI can aid in differentiating such a manifestation from a pyogenic abscess. This is especially relevant in the context of an underlying systemic infection. Adequate and timely therapy can result in complete response without neurologic deficits. Differential diagnosis between glioblastomas and metastatic lesions is often impossible based on conventional MRI. Yet, they have a vastly different therapeutical approach. The aim of the study was to evaluate the ability of 3-T physiological MRI in the discrimination of these common tumor types. METHODS: Thirty-seven patients with glioblastomas and 15 patients with metastatic lesions were examined prior to treatment with conventional MRI followed by MR spectroscopy, diffusionweighted imaging, and perfusion-weighted imaging. The diagnostic accuracy of these parameters was estimated based on receiver operator characteristic curves. RESULTS: Significant differences were found in NAA/Cr area ratios (P ¼ 0.013), Cho/Cr area (P ¼ 0.014), and height (P ¼ 0.023) ratios between glioblastomas and metastatic tumors. The most prominent differences, however, were observed in Cr/Cr2 area (P ¼ 0.006) and height (P , 0.001) ratios as well as in apparent diffusion coefficient (ADC) (P ¼ 0.002) and ADC ratios (P ¼ 0.017). The diagnostic accuracy of Cr/Cr2 height ratio and ADC was 0.92 and 0.86, respectively. When ADC was added to the Cr/Cr2 height ratio, 96% of glioblastomas and 90% of metastatic tumors were correctly classified (94.3% of the cases). CONCLUSION: MR imaging seems to be able to differentiate between glioblastomas and metastatic lesions. Differences in Cr/Cr2 ratio probably reflect diverse metabolic energy pathways in this new biomarker whose significance needs further investigation. Diffusion imaging seems to have a complimentary role while perfusion measurements do not. for open glioblastoma resection comprise a rather neglected category characterized by unawareness and uncertainty concerning the appropriate treatment strategies and overall prognosis. The aim of this study is to identify physiological MR imaging biomarkers that can be measured non-invasively and help predict the outcome in patients with newly diagnosed, non-operable tumors. METHODS: Twenty-four patients with gliomas were identified who were deemed inoperable on the basis of performance status and/or position of tumor. All had
RA-26. USE OF MR SPECTROSCOPY AND DIFFUSION TO DIFFERENTIATE GBM FROM SOLITARY CEREBRAL METASTASES
RA-27. CHO/CR RATIO APPEARS TO BE AN INDEPENDENT IMAGING BIOMARKER OF SURVIVAL FOR PATIENTS NOT SUITABLE FOR OPEN RESECTION OF GLIOBLASTOMA
standard diagnostic MR imaging with diffusion-weighted imaging, perfusion-weighted imaging, and single-voxel PRESS spectroscopy. RESULTS: Using Kaplan-Meier curves to identify possible physiological imaging biomarkers of patients' survival, only Cho/Cr area (P ¼ 0.003) was found to be significant for patients' survival. Neither relative cerebral blood volume nor apparent diffusion coefficient values were important for patients' survival. A derived Cox proportional hazard regression model was found to be a significant contribution to patients' survival (chi-square ¼ 19.051, P ¼ 0.002). Tumor volume (P ¼ 0.046), radiotherapy (P ¼ 0.005), and Cho/Cr area ratio (P ¼ 0.012) were independent prognostic factors for patients' survival. CONCLUSION: This study found that Cho/Cr area ratio may be an important physiological MR imaging biomarker for the survival of patients with non-resectable glioblastomas, permitting measurement of the intrinsic aggressiveness and the anticipated survival when even histological confirmation is sometimes not possible. This may be useful in future treatment trials for this important, though neglected, group of patients, but it needs confirmation in a larger study. 1 with improvement in clinical symptoms, contrast enhancement volumes, and vessel leakiness by volume-corrected K-trans in 12 patients. The effects on brain edema and correlates to complications were further investigated with dynamic contrast-enhanced (DCE) perfusion and diffusion tensor imaging (DTI) measurements. METHODS: Fractional anisotropy (FA) and apparent diffusion coefficient (ADC) of regions of interest (ROIs) involving the contrast-enhancing (CE) portion, non-enhancing (NE) T2 hyperintense portion, contralateral normal-appearing brain (similar location to the CE), and DCE perfusion measurements of the CE areas were obtained. Longitudinal changes and relationship to treatment complications were retrospectively analyzed. RESULTS: There were significant reductions of the extracellular extravascular volume fraction and vessel leakiness (by K-trans) without volume correction. Trends were noted for reduction in ADC and increases in FA for NE. Treatment complications (occlusive small vessel strokes and venous thrombus) were common when the ratio of ADC values of CE ROI over contralateral ROI at baseline was low (P ¼ 0.030), and when the NE FA value did not initially increase by 20%. If NCE FA value initially improved but later decreased by .10% during further monitoring, all 4 patients had concomitant/subsequent complications or need for repeat dosing with bevacizumab, but only 1 of 4 patients without a drop had a complication. The initial reduction in median fractional plasma volume was less in patients with complications than those without (P ¼ 0.007). CONCLUSION: Treatment with bevacizumab likely reduces the free water content/brain edema and vessel leakiness associated with radiation necrosis within 6 weeks. The baseline ADC and monitoring of DTI/DCE values may predict thrombosis and/or ischemia, which may relate to the relative paucity of free water. To study the value of perfusion and conventional MR imaging in the prediction of survival in patients treated with temozolomide (TMZ) chemo-irradiation for newly diagnosed glioblastoma multiforme (GBM). METHODS: In this prospective cohort study, we included patients who were scheduled for radiotherapy in combination with concomitant and 6 cycles of adjuvant TMZ for newly diagnosed GBM. MRIs were obtained at regular intervals: postoperatively (ie, prior to the concomitant phase; time point 1 [TP1]), prior to the adjuvant phase (TP2), and after 3 adjuvant TMZ courses (TP3). Conventional MR tumor size was defined as the product of the 2 largest perpendicular transverse T1-weighted enhancing tumor diameters. Perfusion MR imaging was used to assess quantitative relative cerebral blood volume (rCBV) measurements of the contrast-enhanced areas of maximal perfusion. Overall survival (OS) was used as the outcome variable. The value of conventional and perfusion MR parameters in predicting OS was examined using Cox regression analyses, in which the effects of both absolute and relative changes in tumor measurements during treatment on OS were estimated. RESULTS: Thirty-seven patients were included, in whom 101 conventional and 91 perfusion MRIs were performed. Absolute tumor measurements both on conventional and perfusion MRI did not contribute significantly to the prediction of OS. In the analyses estimating the effect of the change in MR tumor characteristics, the relative change only in conventional MR tumor size from TP2 to TP3 did have a significant correlation with OS (P , .01). CONCLUSION: Perfusion MR imaging did not contribute to the prediction of OS during TMZ chemoradiotherapy for newly diagnosed GBM in this study. To create a radiogenomic map, linking MR imaging traits with gene and miRNA expression profiles, in patients with glioblastoma multiforme (GBM) to determine genomic correlates of an edema MRI radiophenotype to possibly find new genomic targets for GBM treatment. Here, we present the first quantitative study examining radiogenomics in GBM to determine novel and targetable edema biomarkers in GBM. METHODS: We retrospectively identified 82 treatment-naïve GBM patients from The Cancer Genome Atlas who had both genetic expression profiles and neuroimaging. Image analyses was done using slicer 3.6 (slicer.org) and reviewed in consensus by 2 neuroradiologists. The T2/FLAIR was fused and registered to the post-contrast T1WI. Volumetric segmentation was performed and the tumor size corrected edema volume computed. Biostatistics analysis was performed for gene and miRNA sets where the median edema score was taken as the cutoff to define high and low groups (high and low edema ratio, respectively). These groups were then analyzed by Comparative Marker Selection (Broad Inst.). A total of 12,764 genes and 555 microRNAs were analyzed. The most upregulated mRNAs/miRNAs (n ¼ 100) were analyzed with ingenuity pathway analysis (IPA). RESULTS: IPA identified gene and microRNA networks, as well as canonical and functional pathways highly associated with cancer, inflammatory response and disease, cell-to-cell signaling and interaction, and cell death. The top functional networks were RNA damage and repair, cell migration, cell morphology, cellular assembly, and organization. CONCLUSION: The edema radiophenotype identified genes and miRNAs, corresponding molecular networks, and canonical genetic pathways that were highly associated with cell signaling and inflammatory disease, as well as cell migration and morphology. We were able to identify possible key genes and miRNAs for edema-genesis, cell migration, as well as increased inflammatory response. These represent possible new targets for edema reduction and therapeutic augmentation in GBM. Radiotherapy (RT) is an integral component in managing patients with glioma, but the damage it may cause to healthy brain tissue and quality of life is of concern. Susceptibility-weighted imaging (SWI) has recently revealed the presence of hemosiderin-containing microbleeds years after receiving radiotherapy (RT). This study's goals were (1) to use SWI to characterize the evolution of microbleeds in normal-appearing brain tissue that result from RT and (2) to determine whether the administration of an anti-angiogenic agent altered this process. Serial high-resolution, T2*-weighted SWI was acquired on 17 patients with high-grade glioma over the course of 8 months to 4.5 years post-treatment (65 total scans). All patients received xRT with adjuvant chemotherapy. Nine newly diagnosed GBM patients were also treated with a PKC-inhibitor anti-angiogenic (AA) therapy. Microbleeds were identified as discrete foci of susceptibility not corresponding to vessels, tumor, or surgical infarct on consecutive slices. Microbleeds were counted in normal-appearing brain, excluding contrast-enhancing tumor and acute hemorrhage. The number of microbleeds increased with time in all patients, with initial onset occurring between 8 and 22 months. No microbleeds disappeared once formed. The average rate of microbleed formation significantly increased ( 3.5-fold) after 2 years post-RT compared to before (P , 0.001). Patients with AA Tx exhibited fewer microbleeds overall (P , 0.05) and a significant reduction in initial rate of microbleed appearance (P ¼ 0.01), supporting the hypothesis that AA drugs have a radioprotective effect on microvasculature. No trends between microbleed size and onset were observed. Microbleed morphology was classified as: (1) stable in size, (2) enlarging in size over time, or (3) initially appearing then remaining large. Some microbleeds appeared in locations without prior visible vasculature, while others stemmed from deteriorating neighboring veins. Current work focuses on quantifying the size and spatial distribution of microbleeds over time, correlating the number and location of microbleeds with radiation dose, and evaluating the effect of other AA therapies.
RA-31. RADIOGENOMIC MAPPING IN GBM IN PATIENTS
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RA-33. RECURRENT GLIOBLASTOMA MULTIFORME: IMPLICATION OF NONENHANCING LESIONS ON BEVACIZUMAB TREATMENT Daniela Alexandru, Daniela Bota, and Mark E. Linskey; UCI Medical Center, Orange, CA Glioblastoma multiforme (GBM) is the most common primary brain tumor, accounting for 15-20% of all intracranial tumors. It is a very aggressive neoplasm with a median survival from diagnosis of 6 to 18 months. Despite aggressive resection and chemoradiation, the tumor always recurs. MR imaging is an essential tool for diagnosis, treatment planning, and following response to treatment. However, the imaging features of recurrent GBM may be challenging, particularly in patients undertaking novel antiangiogenic therapy. We present such a case treated with repeated surgeries, combined chemoradiation, and bevacizumab. A 51-year-old man underwent gross total resection of left temporal lobe GBM. The tumor recurred 1 year later, requiring a second resection followed by a full course of radiotherapy and temozolomide. Three months after the completion of his treatment, the tumor recurred again. The patient was started on bevacizumab and irinotecan and benefited from this regimen with a 6-month progression-free survival, with clinical stability. However, his neurologic status then went on to suddenly worsen and he died within weeks. Follow-up MRI obtained every 2 months initially showed no progression of the focal tumor on antiangiogenic therapy. However, the last MRI showed multiple, non-contiguous new areas on various imaging sequences, including new discrete FLAIR signal foci, focal contrast-enhancing lesions, diffuse reticular enhancement, and periventricular non-enhancing signal changes. Since the MRI changes were protean and suggestive of multiple etiologies, including radiation-induced changes, radiation necrosis, and progressing tumor, a decision was made for multiple biopsies. As such, multiple lesions with different imaging characteristics were biopsied. All the sampled lesions were reported by pathology as recurrent GBM. In patients treated with bevacizumab, FLAIR hyperintensity signifies tumor infiltration and growth rather than radiation change or even peritumoral edema. FLAIR sequences should always be used to evaluate progression in this particular clinical setting since this sequence provides early evidence of recurrence. In association with our studies for developing a stem cell (SC)-based therapy for the treatment of glioblastoma (GBM), we compared the pathotropism of 2 SC sources, human mesenchymal stem cells (hMSCs) and fetal neural stem cells (fNSCs), toward 2 GBM models: circumscribed U87 and highly infiltrative GBM26. We used conventional and contrast-enhanced MRI at 14.1 Tesla and monitored the location of hMSCs and fNSCs labeled with micron-size iron oxide particles (MPIOs). To assess pathotropism, SCs were injected in the contralateral hemisphere of mice with U87 tumors. MPIO-induced hyposignals showed SC tropism to tumor for both SC types. SCs were found to localize first (day 3 to 7) at the tumor rim. At later time points (day 5 to 7), SCs were also found within the tumor mass. To monitor SC biodistribution after intratumor injection, MPIO-labeled hMSCs and fNSCs were injected intra-tumorally in mice with U87 or GBM26 tumors. Both SCs were found to distribute throughout the tumor in both GBM models. Interestingly, in the U87 model, areas of hyposignal co-localized first with the post-Gd-enhancing regions (ie, regions of high vascular permeability), consistent with SC tropism being induced by vascular endothelial growth factor. In the GBM26 model, no rim of hyposignal was found, consistent with the diffusely infiltrative nature of GBM26 cells. Prussian blue, endothelial growth factor receptor staining and Dragon Green fluorescence revealed a localization of iron from MPIO-labeled SCs that was consistent with the MR images. Staining for macrophages and tumor cells showed that MPIOs were absent in both those cell types and suggested that the MPIOs remained within the labeled SCs. In summary, our results indicate that hMSCs and NSCs exhibit similar properties as concerns tumor tropism and intratumoral dissemination, and that MPIO labeling of SCs is a promising approach to pursue for localizing SCs in patients who receive stem cell therapy. The detection of infiltrating brain tumor cells beyond the traditional contrast-enhancing region continues to be a challenge for the treatment of brain tumors. Cases presenting with aggressively infiltrating diffuse tumors present a particularly challenging radiographic problem, as it is difficult to determine tumor extent. This study compares voxel-wise in vivo MRI data to ex vivo brain tissue following expiration and brain dissection. METHODS: One 70-year-old male patient with an unoperated brain tumor was evaluated for this study. The patient initially presented with a diffusely infiltrating WHO grade II astrocytoma, as determined by stereotactic biopsy. The patient underwent radiation treatment, with concomitant temozolomide, radiographically progressed, and began treatment with bevacizumab. Following 3 cycles, subtle radiographic progression was noted, and accutane was added, followed by the reintroduction of temozolomide. The patient's final imaging study was acquired 17 days prior to death. The patient consented to brain donation to our research institution, and his brain was fixed in formalin solution and sliced 2 weeks later using a custommade rig designed to allow for slicing in the same axial orientation as the gathered imaging. Histological samples were taken from 7 2 x 2-cm regions exhibiting suspicious imaging findings and 1 additional region with normal-appearing brain. Samples were paraffin-fixed and cut into 5-mm sections. Standard H&E staining was performed, and a final diagnosis of
RA-35. VOXELWISE CORRELATION OF IN VIVO MRI TO EX VIVO BRAIN TUMOR HISTOLOGY
